New drug zavicefta under Real-World watch for sepsis and kidney patients

NCT ID NCT06864585

Not yet recruiting Knowledge-focused Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will observe how safe and effective the antibiotic Zavicefta is when used in everyday medical practice in Japan. It includes 59 patients with sepsis (a severe blood infection) or reduced kidney function who are receiving Zavicefta for the first time. Researchers will track side effects and how well the drug works over 28 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

impaired renal function disease infectious disease infectious disease with sepsis kidney failure Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••